[Encephalitis as a neurological manifestation of COVID-19].

Encefalitis como manifestación neurológica del COVID-19.
COVID-19 Encefalitis Encephalitis Manifestaciones neurológicas Neurological manifestations Neurology Neurología SARS-CoV-2

Journal

Medicina clinica
ISSN: 1578-8989
Titre abrégé: Med Clin (Barc)
Pays: Spain
ID NLM: 0376377

Informations de publication

Date de publication:
13 08 2021
Historique:
received: 01 03 2021
accepted: 04 03 2021
pubmed: 3 6 2021
medline: 3 8 2021
entrez: 2 6 2021
Statut: ppublish

Résumé

In the context of the global COVID-19 pandemic, the different clinical manifestations of this infection pose a challenge for healthcare professionals. Respiratory involvement, the main symptom of SARS-CoV-2 infection, means that other manifestations, such as neurological, take a back seat, with the consequent delay in diagnosis and treatment. All COVID-19 patients admitted with neurological symptoms or diagnosed with encephalitis since March 2020 in a tertiary hospital in Zaragoza, Spain. Two patients with COVID-19 infection confirmed by nasopharyngeal PCR and whose clinical picture consisted of neurological alterations compatible with encephalitis. Cerebrospinal fluid (CSF) microbiology was negative for bacteria and viruses, including SARS-CoV-2 but, given the clinical suspicion of encephalitis due to the latter, antiviral treatment with immunoglobulins and plasmapheresis was started early. Despite this, the evolution was not satisfactory. COVID-19 encephalitis is a recently described clinical entity, whose pathophysiology is still unknown and no treatment with clinical evidence is available to date.

Identifiants

pubmed: 34074474
pii: S0025-7753(21)00215-3
doi: 10.1016/j.medcli.2021.03.008
pmc: PMC8164469
pii:
doi:

Types de publication

Case Reports Journal Article

Langues

eng spa

Sous-ensembles de citation

IM

Pagination

141-143

Informations de copyright

Copyright © 2021 Elsevier España, S.L.U. All rights reserved.

Références

J Neurovirol. 2020 Apr;26(2):143-148
pubmed: 32447630
J Clin Neurosci. 2020 Jul;77:8-12
pubmed: 32409215
Neurol India. 2020 May-Jun;68(3):560-572
pubmed: 32643664
Am J Emerg Med. 2020 Jul;38(7):1549.e3-1549.e7
pubmed: 32425321
Front Neurol. 2020 May 22;11:518
pubmed: 32574248
Neurocrit Care. 2020 Jun;32(3):667-671
pubmed: 32346843
Brain Behav Immun. 2020 Jul;87:149
pubmed: 32387508
Brain Behav Immun. 2020 Aug;88:945-946
pubmed: 32283294

Auteurs

Herminia Lozano Gómez (H)

Servicio de Medicina Intensiva, Hospital Clínico Universitario Lozano Blesa, Zargoza, España. Electronic address: fiex_hermi1990@hotmail.com.

Ana Pascual Bielsa (A)

Servicio de Medicina Intensiva, Hospital Clínico Universitario Lozano Blesa, Zargoza, España.

Paula Abansés Moreno (P)

Servicio de Medicina Intensiva, Hospital Clínico Universitario Lozano Blesa, Zargoza, España.

María Pilar Luque Gómez (MP)

Servicio de Medicina Intensiva, Hospital Clínico Universitario Lozano Blesa, Zargoza, España.

Almudena Matute Guerrero (A)

Servicio de Medicina Intensiva, Hospital Clínico Universitario Lozano Blesa, Zargoza, España.

Juan José Araiz Burdio (JJ)

Servicio de Medicina Intensiva, Hospital Clínico Universitario Lozano Blesa, Zargoza, España.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH